Sartorius (FRA:SRT3) received a €110.00 ($127.91) price objective from stock analysts at Berenberg Bank in a research note issued on Thursday. The firm presently has a “neutral” rating on the stock. Berenberg Bank’s target price suggests a potential downside of 9.98% from the stock’s previous close.
Shares of SRT3 opened at €122.20 ($142.09) on Thursday. Sartorius has a 12-month low of €71.00 ($82.56) and a 12-month high of €124.70 ($145.00).
Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Featured Article: What is the Book Value of a Share?
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.